Drug Trial Radar · NCT02621931
Comparing Efficacy and Safety of 2 Dose Regimens of Subcutaneous Administration of TEV-48125 Versus Placebo for the Preventive Treatment of Chronic Migraine
Last checked: Nov 19, 2026Latest source record: Nov 9, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,130
Actual
Start
Mar 22, 2016
Primary completion
Apr 11, 2017
Study completion Apr 11, 2017
Sponsor
- Lead sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.Teva (TEVA)
- Sponsor type
- Industry
- First posted
- Dec 4, 2015
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study is being conducted to evaluate two doses of TEV-48125 in adult patients with chronic migraine
Conditions
- Migraine
Interventions
FremanezumabDrug
Fremanezumab was provided as a sterile, unpreserved, aqueous solution for injection, 225 mg/1.5 mL pre-filled syringe for single-use administration. The 675 mg dose was given as 3 injections; doses of 225 mg were given as a single injection. Study drug was administered at the clinical site.
PlaceboDrug
Placebo 1.5 mL pre-filled syringes identical in appearance to active intervention. Study drug was administered at the clinical site.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in the Monthly Average Number of Headache Days of At Least Moderate Severity During the 12-Week Period After the First Dose of Study DrugTime frame: Baseline (Days -28 to Day -1), Treatment (Days 1 - Week 12)
- Participants With Treatment-Emergent Adverse Events (TEAEs)Time frame: Day 1 to Week 12
Locations
273 sites in 9 countries. Site status is shown where the registry gives one.
Teva Investigational Site 13628
Birmingham, Alabama
Teva Investigational Site 13577
Birmingham, Alabama
Teva Investigational Site 13577
Birmingham, Alabama
Teva Investigational Site 13628
Birmingham, Alabama
Teva Investigational Site 13606
Phoenix, Arizona
Teva Investigational Site 13579
Phoenix, Arizona
Teva Investigational Site 13579
Phoenix, Arizona
Teva Investigational Site 13606
Phoenix, Arizona
Teva Investigational Site 13602
Little Rock, Arkansas
Teva Investigational Site 13602
Little Rock, Arkansas
Teva Investigational Site 13568
Encino, California
Teva Investigational Site 13568
Encino, California
Teva Investigational Site 13546
Fullerton, California
Teva Investigational Site 13546
Fullerton, California
Teva Investigational Site 13540
Long Beach, California
Teva Investigational Site 13540
Long Beach, California
Teva Investigational Site 13632
Redlands, California
Teva Investigational Site 13632
Redlands, California
Teva Investigational Site 13571
Redondo Beach, California
Teva Investigational Site 13571
Redondo Beach, California
Teva Investigational Site 13573
San Diego, California
Teva Investigational Site 13573
San Diego, California
Teva Investigational Site 13538
Santa Monica, California
Teva Investigational Site 13538
Santa Monica, California
Teva Investigational Site 13594
Santa Rosa, California
Teva Investigational Site 13594
Santa Rosa, California
Teva Investigational Site 13595
Walnut Creek, California
Teva Investigational Site 13595
Walnut Creek, California
Teva Investigational Site 13629
Aurora, Colorado
Teva Investigational Site 13629
Aurora, Colorado
Teva Investigational Site 13557
Boulder, Colorado
Teva Investigational Site 13557
Boulder, Colorado
Teva Investigational Site 13593
Colorado Springs, Colorado
Teva Investigational Site 13593
Colorado Springs, Colorado
Teva Investigational Site 13633
Denver, Colorado
Teva Investigational Site 13612
Denver, Colorado
Teva Investigational Site 13612
Denver, Colorado
Teva Investigational Site 13633
Denver, Colorado
Teva Investigational Site 13631
Englewood, Colorado
Teva Investigational Site 13631
Englewood, Colorado
Showing 40 of 273 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.